Showing posts with label health care reform. Show all posts
Showing posts with label health care reform. Show all posts

Friday, December 27, 2013

Health Care Reform


The affordable care act is rapidly reconfiguring a massive segment of the entire US economy.  Most estimates I've seen indicate that 1/6 of spending in the United States is on health care.  With the most comprehensive, rapidly evolving, often times unpredictable change rippling through a system most of us encounter in a very personal way, there are going to be winners and losers, and they are likely to be very vocal about it.

Imagine if the captain of the Titanic had seen the iceberg prior to the impact that sank the massive ship and tried to turn the boat with emergency maneuvers.  I imagine passengers would be knocked against the wall, dishes would fall, the boat would lean heavily, people would grab for anything stable.  Confusion and panic would abound. 

I feel like I am living in that moment in healthcare right now.

I wanted to blog about how this reform is affecting my care for patients and the patients I care for.  It is a post that is necessarily limited in scope but it is also very personal and specific.  Like many prior posts on controversial topics, I want to do my best to leave politics out of it.  You may try to guess my political persuasion but I will tell you up front that I am not a believer in either political party. 

So far, the changes seem mostly focused on reforming how care gets paid for rather than how care is actually delivered.   I want to explain how the money works because so much of the debate appears disconnected from reality. 

Private practice oncology is under attack.  Despite the fact that cancer care delivered in the outpatient setting is 30% less expensive than the exact same care provided within hospitals that may be only several yards away, current policies are making it nearly impossible to maintain viable outpatient oncology clinics.  If these trends persist, you will see access to care diminish regionally.  While providers in major cities may find ways to keep patients coming through the doors, practices in more rural areas are closing at an alarming rate.

The infrastructure it requires to continue delivering care cannot be reasonably supported by physicians in small groups.  When there are only 1-3 doctors in a group, the revenue cannot continue to cover the costs of maintaining infusion nurses, insurance verification, reception, pharmacy, back office, clinic nursing and so forth.  While that will disproportionately affect smaller areas, I've written previously about "Doctors going broke" in urban Southern California.  Small groups are getting snatched up by hospitals and struggling to remain independent.  This will have a bad ripple effect for access to care for many patients. 

I am concerned because the way I see the change progressing, I think these trends may be accelerated.  Many of the healthcare changes have been referred to as "bumps along the way."  For any of you who have hit a speed bump while driving 90 miles an hour, you know those bumps can be very destructive.  Now before you Canadians and Europeans get all smug, I hope you can respect that our health care system has evolved very organically over quite a few years.  Change is hard - bear with us.

Cancer care is extremely expensive.  Single doses of drugs that may need to be given every three weeks can cost thousands of dollars.  Effective pills can cost more than several hundred dollars each - which really starts to add up if you take it daily forever (see post about drug costs).

With the new exchange plans, it appears to me that much of the middle class will be considerably more financially vulnerable if they get sick.  If you do not qualify for the generous subsidies given to individuals who earn less than a specific threshold, you may be on the hook for $5000-10,000 deductible repeated annually (on top of premiums).  I can tell you that will be impossible for many of the patients that I see.

So what am I supposed to do if a patient comes to see me and simply cannot afford the visit or the treatment?  While I am wired to believe I should see any patient no matter what the circumstances, there are limits.  I can put myself out of business very quickly if we perform more charity care than we can afford.  If a patient does not or cannot pay, what am I supposed to do?  Our office tries to do just about anything to work with a patient or their family, but sometimes things are never going to be collected and we call that, "bad debt." 

I think most patients are unaware of how drugs are delivered in outpatient oncology clinics.   My office literally purchases all the drugs we plan to administer.  This is a lot like going shopping for groceries -  when we purchase them, payment is due immediately.  Normally we do make this purchase 24-48 hours before the patient is to be seen in clinic.  Often drug is arriving in my office at the same time as my first patients for the day. 

When the patient comes to clinic, we check blood counts, ask about symptoms, etc.  Provided everything seems right, we then administer an "intravenous loan" to the patient which is the cost we paid for the drug.  Over the next 30-90 days, we try to get the insurance and the patient to repay the loan.  If that system breaks down, the money we paid for the drug never comes back.  Even single doses of some expensive drugs can be a genuine nightmare if we don't get reimbursed.  Imagine loaning your car to someone and then finding out they were not going to bring it back.  Sometimes those same individuals come back asking for another car (treatment) as if keeping the first one wasn't a major problem.  If "bad debt" percentage goes up even a little, it is a huge problem.  This is a number we monitor extremely closely because of the enormous impact it makes.  I worry that "bad debt" will skyrocket when patients become financially responsible for more of their care.

While some may conclude that giving chemotherapy must be very profitable because of how expensive drug are, keep in mind that they are just as expensive for us to purchase and the government limits how much we can charge for administering drugs.  The "average price (ASP) plus 6%" rule for medicare sets caps on prices.  Some may argue that 6% could be a lot of money, but keep in mind that has to cover the cost of infusion nurse staff, pharmacy staff, infusion equipment, etc.  Furthermore, the sequester knocked that back by 2% to ASP+4% and was the final blow for many oncology practices that had to radically restructure their practices to keep things afloat. If a "2% reduction" to reimbursement rates killed some practices, imagine what happens when bad debt goes from 1% to 7% or more....

In cancer care, it probably isn't a surprise that a lot of our patients are in Medicare - but not all are.  Indeed there can be enormous variations depending on whether your community has a lot of older patients or not.  For those patients with private insurance, we have to re-negotiate our contracts with insurance companies like Blue Cross, Aetna, etc. every few years.  The contracting always starts with Medicare rates then either goes up or down depending on the relative strength of the insurance company or the provider group.  Some oncologists have contracts with major insurers that are better then Medicare, some oncologists have contracts that are worse.  These contracts then determine how much a service in the office gets reimbursed.  The physician offices with one or two docs, simply have zero leverage in these negotiations.  They either accept the rates offered to them or they get excluded and made "out of network."

Settling these contracts requires is the full time job (practice expense) of one of our office employees.  In recent news reports from California, some of the exchange plans have come in offering rates that are simply too low to enable the doctors to keep their doors open if they were to accept those contracts.  That is why you are seeing "skinny networks" or networks with very small groups of providers who are able to accept the contract.

Many patients may simply not understand how much it costs to keep the doors open.  If you completely exclude the cost of drugs, and only factor in things like rent, staff compensation, malpractice insurance, etc, and simply add up those costs and divide by the number of patients I see in a day it results in a "cost to see patient" that averages several hundred dollars.  Literally, when I walk through the door to see a patient (one who is just coming in and not getting treatment), I have spent several hundred dollars to do so.

Obviously the more patients I see with the same resources, the lower the cost per patient, but you can only take that so far.  On an average day, I may see over twenty patients, and on a extremely busy day, I can see thirty.  In the last several years, as reimbursement pressures have gotten harder everyone has tried to compensate with seeing larger volume of patients.  Unfortunately, as that margin gets closer and closer to zero, you simply cannot humanly make it up by volume.  In some cases (contracts) you actually loose money every time you see a patient but you do it because it is the right thing to do.  Obviously, the more such patients you see, the faster you reach financial oblivion.

So this is where I have to return to the impending changes.  Very soon, patients are going to be more financially responsible for their care than ever before.  Enormous deductibles and larger copayments are going to become financially devastating to more and more individuals.  As that destruction unfolds, it is going to take down a lot of community practice oncology sites who see their bad debt skyrocket.  "Bad debt" is set to explode and I cannot predict how broadly the damage will extend.

Patients are going to avoid care a lot longer hoping that the pain in their side goes away rather than incurring a $4000 personal bill for an ER visit that makes a diagnosis.  We will begin to see patients with far more advanced disease because they delayed things too long, or their docs were too busy to get them in quickly enough.  Annual deductibles will become an extraordinarily painful reminder of a chronic illness.  I have to imagine that CLL patients may fully exhaust their deductible every year.  Many people are just not in a position to cough up 10K per year if that is what their plan requires.

While much of the above discussion only applies to the 5 million patients who lost their insurance in the "individual market" and were kicked into the exchanges, next year we see the employer mandate begin.  This may impact an enormous number of individuals who get their insurance through their work.  Everything that is happening to patients in the individual marketplace is going to happen on a much larger scale when employer plans lose their grandfather status. 

Some readers will see this and conclude that it is finally time for a "single payer health system" ie. Medicare for all.  Frankly, I predict that come Jan 1 when a lot of individuals discover they don't have insurance because the application process was so broken (Oregon's webpage still has yet to enroll a single patient), you will hear demands to allow these people to "temporarily" be given Medicare coverage.  What happens after all to the patient who has paid their premium faithfully and covered their bills with my office for years but now needs treatment and they have lost their coverage because of a broken system?

If we go to single payer though, Medicare will have to be radically restructured.  My practice did an analysis of what would happen if every patient we saw suddenly had their contracts revert to "medicare rates."  After reviewing the consequences, we all agreed this would be our "Armageddon."  We would go from a practice that is surviving to one in which none of the doctors would receive ANY income from working and EVERY DOCTOR would all have to pitch in thousands of dollars PER MONTH keep the doors open.

Naturally, that means we would not be able to keep our doors open in our current structure.  The city of Eugene would lose significant access to cancer care and patients might have to drive two hours to find it in Portland - provided it was available there.  While that sounds terrible, it is already happening throughout the country in many places and the biggest changes have yet to hit.

I am sorry if this is such a sour post.  I know I typically aim for optimism, but I am having a hard time getting there when I think about the changes I am seeing. 

Thanks for reading.

Wednesday, June 26, 2013

The doctor is out???

I've written several times about the harsh economic environment in which oncology practices are trying to survive.  Many of the people who debate health care reforms and policies have clearly never operated a private practice because the decisions they have made are completely destroying the infrastructure for cancer care in the United States.

This article spells out just how bad things are right now:

Cancer Clinic Closings And Consolidation: Ongoing Cuts To Care And Increasing Treatment Costs


In short:

The COA Impact Report reveals continued negative trending in the nation's cancer care delivery system.  During the past six years 1,338 clinics and practices have been impacted as follows:
  • 288 individual clinic sites closed
  • 407 practices are struggling financially
  • 43 practices sending all patients elsewhere for treatment
  • 469 practices have entered into contractual relationship or have been acquired by a hospital
  • 131 practices have merged or been acquired by an entity other than a hospital 
This all happened PRIOR to the sequester which accelerating the destruction (see prior post)

If you doc seems more stressed out than usual - or you can't get an appointment - this issue is very real and very important.  Thanks for your support and thanks for reading.

Thursday, May 23, 2013

Medicare killing personalized medicine....?

Just when you thought we might see some enormous breakthroughs in CLL/NHL molecular testing (see my posts on CLL prognosis, prognostic marker definitions, molecular prognosis in DLBCL) Medicare comes along and squashes progress....

Two recent articles by Scott Gottlieb spell out how new molecular tests get started and the important role Medicare plays in setting policies that apply to ALL insurance (yes - even if you don't have medicare, when they make a change, so does Blue Cross etc)


 
In CLL, we are on the cusp of new molecular testing strategies that will help inform the optimal treatment for an individual patient, clarify their prognosis like never before, and even help identify patients where watch and wait may be a particularly beneficial strategy.

When Medicare makes a ruling, it can be very difficult to turn things around unless patients step up and make noise.  Not sure how this one will play out in the end but hopefully such testing will be able to move forward.

Thursday, May 16, 2013

Drug Costs - By State?

I already put up a post explaining why drugs cost so much.  Essentially it has to do with an enormously expensive process of drug development, the high rate of drug failure, the frequency of the diagnosis, and good old fashion profit.

One out of four patients walks away from the pharmacy counter without their medications when they are told the co-payment is $500 or more.  For new CLL/NHL drugs (lenalidamide, ibrutinib, idelalisib, etc.) lots of people will be encountering that sort of bill. 

Under new health-care regulations the price you pay may vary considerably based upon the state you live in and the rules imposed upon insurers on account of their individual exchange policies.

Look for patients in California to find another reason to leave the state (like I did).  New York on the other hand looks pretty good.  Can't wait to see what states like Texas and Oregon do (on either end of the political spectrum).

Once again, the law of unintended consequences makes things harder on quite a few people. 

Thursday, May 9, 2013

When bad ideas go badly....

I've written previously about the impact of the Sequester on community oncology practice.  In short it is REALLY HURTING cancer patients access to affordable care.  Ironically it is also increasing the cost of delivering the exact same care.

Here are the results of a survey that shows the extent of the impact.

Please contact your local representative and let them know your concerns about access to care.  This is a big deal and a bunch of colleagues I know around the country are making significant changes to their practice.


Friday, May 3, 2013

How expensive are new drugs?

Ibrutinib, idelalisib, GA-101 (aka obinatuzumab - if I got that right), ABT-199, etc.  The tidal wave of new drugs is exciting because we will soon be treating the disease with therapies that are very effective and lack many of the side effects of chemotherapy. These are some of the exciting new drugs coming soon for patients with CLL and NHL.  Unfortunately they will probably also break the bank.  I bet that ibrutinib costs about $150k per year... that is my prediction.

CML is a leukemia that has a lot in common with CLL.  It is a slow cancer that affects about 10k new patients per year.   Historically (before the year 2000) patients lived a number of years (3-5) with the disease and put up with a bunch of lousy chemotherapy drugs that didn't do much.  Eventually the disease took on a nasty personality (like richter's transformation) and the patient died of "blast crisis."

That all changed in 2000 when a new "wonder pill" called Gleevec made the disease vanish from patients blood.  A single, once a day medication literally changed overnight what it meant to hvae the diagnosis of CML.  Newer, more sensitive molecular tests were required to even detect the disease that could no longer be seen by standard tests like, "cytogenetics."  Sounds familiar right?

Gleevec cost about $40k/year when it first came out (we can talk about how much that price has risen later).  While that number seems extremely high - it is inexpensive compared to many of the new drugs for cancer. 

Why so high?

I have a prior post about why drug development takes so long.  It might be a good read for starters because it can help explain why the process is long and expensive.  A landmark study from 2002 estimated that the total research and development costs of a new drug was about $800,000,000 (eight hundred million dollars).  That is the price for a drug that actually gets approved.  Then you need to take into account all of the drug failures.  There are a ton of drugs that get made that never even enter human clinical trials.  Of the ones that enter phase 1 testing, somewhere between 5-20% will ever see a successful phase 3 trial and get approved. 

Join the high cost of drug development and the high rate of failure and you have a formula for expensive drugs - but that still misses one critical ingredient - what is the frequency of the disease?  If you are making a new drug for cholesterol, you can treat just about everyone in America.  If you are making a drug for angioimmunoblastic T cell lymphoma - you have to recoup your costs on the backs of the 1000 patients per year that get the diagnosis.  The formula goes something like: (drug development costs divided by number of patients = drug price). 

One irony is that the number of new patients diagnosed with CML per year hasn't changed, now that patients are living much longer, CML has actually become quite common.  Every oncologist probably has a handful of CML patients in their clinic because instead of living 3-5 years, they now all live almost normal lives.

Ok, I think most readers at this point can agree that drugs for CLL and NHL will be expensive.  Many readers will agree that the drug developers should be rewarded for taking enormous risk and bringing new effective drugs to patients with cancer.  Some would say that we should just have government funded research and that would make drugs more affordable.  Unfortunately, I've seen both government supported research and pharma research up close.  If we relied on government based research to bring new drugs, I think we would still be stuck with chlorambucil. 

But at what point does a drug price go from being a fair reward for innovation to profiteering off vulnerable cancer patients?  In the last ten years we have seen remarkable breakthroughs in cancer treatment but it doesn't always seem like price and effectiveness are totally linked.  Some new drugs are small incremental improvements while others are truly revolutionary.  What is odd is that the difference between a "single" and a "homerun" have no impact on cost.  Any new cancer drug is more than $100k/year.  Academic thought leaders have taken note and for the first time we are seeing organized pushback. 

One clue to me that we are in an era of profiteering is that the price of a new drug seems more linked to what the price of the most recently approved drug was rather than how effective the new drug is.  In the case of Zaltrap - a newly approved drug for colon cancer that didn't move the needle too far in terms of effectiveness (ie. new mechanism but not a whole lot more effective) the price was right on mark with other recently approved drugs (over 100k per year).  Fortunately the organized rebellion of academic thought leaders has resulted in a decreased price for this drug. 

I believe that market forces are able to result in fair prices in most situations.  The problem with medical care is that it isn't a normal market.  When you go to buy a car, you figure out what something is worth and you decide if the dealer is selling it for a fair price.  If not, you walk away.  In medicine though, how do you put a value on keeping your hair?  Staying at your job instead of taking sick leave?  How do you decide the value of an additional year of life.  Is that the same for a 25 year old as an 85 year old?  Value determinations are difficult.  Furthermore, in medicine you may have your co-payments but chances are some anonymous third party is paying the lion share of the cost.  Who wouldn't want the latest and greatest if they don't have to foot the bill.  Add to that the lack of choice.  You can't just go down the street to a different car dealer when it comes to picking a therapy in lymphoma.  Without market forces, drug prices get all out of whack.

If we come back to the price of Gleevec it is interesting that the price has risen over the years.  Two newer drugs came along (sprycel and tasigna) that had prices set around the going rate when those drugs were approved.  Oddly enough, Gleevec rose too.  The drug didn't get better, it's peers got more expensive and they were able to rise closer to their peer group.  This has drawn the focused criticism of many CML docs as well as a rebuttal from the maker of two of these drugs.  It will be interesting to watch what happens to all three drugs when Gleevec goes generic soon.  A generic drug can sometimes drop in price by 90% overnight.  Sprycel and tasigna are better than Gleevec but I bet the price of all three drop considerably.

I think most patients who see these prices for their care experience some disbelief and anger.  It is hard to know where to place that anger and sometimes that falls upon the drug companies, sometimes the insurance companies, and sometimes even the doctors caring for the patient.  I can tell you as a docs are not the ones making much money - in fact some docs are closing up shop or refusing to see Medicare patients because they can't deal with the costs anymore.  Any simple answer probably misses a lot of complexity.

It is clear to me that the current trajectory is unsustainable.  I watched in amazement as Peter Hillman gave an analysis of the impact of new CLL drugs on the overall spending of the British Health Service.  New CLL drugs alone could tank the British cancer funding system.  I credit the British for having a system that also takes into account the cost of drug in determining coverage.  In the US it is strictly about safety and efficacy.  Drug prices are not a factor in determining approval.

I am not sure I can offer solutions without getting too political. We all want new drugs but in a broken marketplace you cannot expect "fair prices" to sort themselves out.  I'm not even sure that a "single payor system" could afford the innovation we are seeing now.  I think the best thing we can all do right now is get involved in clinical trials so that there are a bunch of new BTK or PI3K inhibitors out there to restore some degree of choice.

Wednesday, April 3, 2013

Why oncologists may refuse medicare patients


Update: A possible solution?
Huffington post article about patients traveling thousands of miles
Generating congressional activity


I don't want this blog to be about politics.  I want this to be a place for educating patients about their disease.  In this case though I need to highlight a topic that carries a lot of political emotions.  Please know that I am not trying to argue left vs right - just to inform patients about some trouble that is brewing.

Our system of health care delivery is really broken.  It was broken before Obamacare and I think a golden moment for positive change was blown up in terrible partisanship.  Both sides carry plenty of blame - this is not about pointing fingers at either side.  While the survival rates for patients with individuals with cancer in the US exceeds many other countries - the way it gets paid for is a true mess.

This headline sounds alarmist - but you need to know about it - and I encourage you to read the article (WP tends to be more conservative in opinions - but the facts of this article reflect pretty closely what I am seeing):

Cancer clinics are turning away thousands of Medicare patients. Blame the sequester.

Taking care of patients with cancer is extremely expensive.  Drugs can cost unbelivable amounts of money.  $5000-$10,000 per dose of some drugs is commonplace (Bendamustine, ofatumumab are over 100k / for a full course of treatment - neulasta 5-6k/dose, Rituxan - 40K/year). 

When an oncologist in community practice (important to differentiate docs who are practicing under a hospital vs independent - right now the split in US is about 40/60% respectively) treats you with a drug, they have to purchase the drug, administer the drug, and hope against hope that they get reimbursed by insurance and that patients pay their co-payments.  Often paymenst may lag by 30-90 days so that entire time docs are essentially "loaning" the drug to the patient until it is repaid by their insurance.  If that ever breaks down - they eat the cost. 

When I was searching for a job after training I interviewed with a practice close to where I grew up - so I could be near family.  I had an offer to join a practice where all the docs ended up declaring personal bankruptcy when their practice got upside down on their drug costs.  They were profiled in this CNN article - the problem is real.

Doctors going broke.
Here is another article - not about the group I personally know

Since many patients with cancer are older - they are frequently covered by Medicare.  A number of years back payment reforms implemented a system called ASP+6% for drugs administered in the doctors office.  It means that when a doctor treats you with rituxan, they get reimbursed the AVERAGE WHOLESALE PRICE of rituxan plus 6%.  Your head can probably run a bunch of scenarios about this and come up with vastly different conclusions.  I will tell you how I see it play out with many docs that I know.

First of all, let's talk about what that 6% is supposed to cover.  In a family practice clinic, there may be 1-3 staff members per doctor.  That includes front desk, medical records, nurse, etc.  In an oncology practice it is often closer to 8-10 staff per doc.  That includes a pharmacist, pharmacy technician, infusion nurse, insurance verification, front desk, medical assistants, etc.  The idea is that the additional complexity of runing an infusion center is covered by that 6%.

The first major assumption is that you can actually buy your drugs for the average wholesale price.  Docs in smaller practices have a difficult time buying their drugs for the same price as a 200 physician network.  Hospitals have a special discount rate that independent docs simply cannot compete with.  AVERAGE means some docs can buy their prices below and some docs buy their drugs for more than what other docs pay.  The more you are above average price, the less revenue is there to run the infusion center.

Heaven forbid you should ever administer a drug and then have insurance deny payment.  One single dose can really hurt when it is 20K.  Sometimes these can be denied retroactively - even if several doses have been given.... I've had it happen (fortunately it wasn't one of the really expensive ones).  Sometimes you can get a drug company to replace the drug - sometimes you can't.

The big issue with the headline above is that the sequester has resulted in a 2% cut in medicare part D payments - so now that reimbursement is ASP +4%.  That represents a 33% reduction in the margin (6-2=4) any docs may have had if they were even able to buy the drug at the average price to begin with.  For many docs the answer is clear - they are personally paying out of their pocket to treat some patients with chemotherapy.  Even margins of -0.5% can be significant if the drug costs 10K and you are paying salaries of your infusion nurses - you simply cannot keep your infusion center open.

As a result, a number of practices are starting to close their practice to patients with medicare as their only insurance.  Hospitals have the ability to charge more for their services than independent docs so they are less effected by these changes.  There has been a tidal wave of docs selling their practice to hospitals because they just cannot afford to provide care independently even though it is generally 30% less expensive to receive care through an independent physician:

Oncologists struggle to stay independent

The first article above indicates that patients may be shifted into hospital based practices.  The reality though is that many smaller communities don't have such groups - in exactly the same place where the problem is most acute.

The point here is that this is a time of great difficulty for a bunch of docs who really care a ton about their patients.  I still love what I do.  It gives me a ton of personal satisfaction to step into a patients life when they are terrified and provide some hope and comfort.  I know not all patients end up with the outcome they want, but even when the outcome isn't going to be good, it makes me feel incredibly good if I can help the patient on their journey.

As hard as it is for docs - I am sure it is even more scary for patients who are not sure where they would get their care if their doc had to close up shop.  I really empathisize with their fear.  I don't want this to be a "boo-hoo" post - I know a lot of people are trying to sort their way through this economic train wreck - both patients and docs. 

I wish I could tell you what you can do - unfortunately I don't see many easy answers.  Let your elected officials know if you experience a lack of access to care or support efforts to reverse these cuts. Let your insurance know how much you value your provider (if you do).  It all seems pretty weak to me quite frankly.

Sorry for the downer post -
Jeff